Advertisement
Screener

Aligos Therapeutics, Inc. (ALGS) Form D

Aligos Therapeutics, Inc. Form D Notices of Exempt Offering of Securities

Notices filed with the SEC for securities sold without registration under Regulation D or Section 4(a)(5), newest first. Values are as filed.

  • 2020-01-16: Federal exemption Rule 506(b); Types of securities offered Equity; Date of first sale 2019-12-23; Total offering amount $125,000,167.
FiledFederal exemptionTypes of securities offeredDate of first saleTotal offering amountTotal amount soldTotal remaining to be soldInvestors who have already invested
2020-01-16Rule 506(b)Equity2019-12-23$125,000,167$85,000,001$40,000,16638

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35
Protalix BioTherapeutics, Inc. (PLX)$0.221B9.87
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
Alector, Inc. (ALEC)United States$0.213B-1.90
Invivyd, Inc. (IVVD)United States$0.270B-2.42
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
Protara Therapeutics, Inc. (TARA)United States$0.198B-3.22